Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: IBI3009

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.